Authors
Latest:
Dr. Zarour on Unmet Needs in MelanomaHassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.
Latest:
Dr. Soliman the Utility of ADCs in Breast CancerHatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.
Latest:
Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02This episode discusses the desired outcomes from the HERTHENA-Lung02 trial that would justify using HER3-DXd before platinum and pemetrexed chemotherapy while also exploring the potential benefits of amivantamab, including its PFS advantage and the observed trend toward improved OS in this treatment setting.
Latest:
Patients Coping With Insomnia May Benefit from Behavioral InterventionsCognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based stress reduction (MBSR) can improve sleep for patients with cancer, but CBT-I continues to be the best nonpharmacologic option
Latest:
Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPCFrontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.
Latest:
Dr. Ali on the Need to Understand Real-World Disparities in BRCA Testing in TNBCHaythem Y. Ali, MD, member, Henry Ford Cancer Institute, Henry Ford Health System, discusses the need to understand real-world disparities with BRCA testing referrals and uptake in patients with triple-negative breast cancer.
Latest:
Dr. Zhu on Mitigating Toxicities of Elective Nodal Irradiation in Breast CancerHe James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.
Latest:
Dr. Cho on Investigational BiTE Therapies in Multiple MyelomaHearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.
Latest:
Adjuvant IO Therapy in Early-Stage NSCLC: The IMpower010 and PEARLS TrialsExpert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.
Latest:
Dr Wakelee on the Implications of the TRUST-II Trial of Taletrectinib in ROS1+ NSCLCHeather Wakelee, MD, FASCO, discusses the significance of early data on the use of taletrectinib in patients with ROS1-positive non–small cell lung cancer from the phase 2 TRUST-II trial.
Latest:
Experts on the Evaluation of CEACAM5-Targeted Therapy in NSCLCBalazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.
Latest:
New Law Widens Access to Genetic Counseling but Licensure and Coverage Barriers PersistTelehealth, a universal term for the use of digital information and communication technologies to remotely access healthcare services, is improving availability of healthcare services, particularly for patients in rural areas.
Latest:
Dr. Dalton on Toxicities in the Frontline Treatment of Ovarian CancerHeather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.
Latest:
Toxicities Associated With VEGF TKIs and Checkpoint Inhibitors in mRCCHeather Greene, a nurse practitioner at West Cancer Center, discusses the toxicities that are associated with VEGF TKIs and checkpoint inhibitors in metastatic renal cell carcinoma (mRCC).
Latest:
Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate CancerHeather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.
Latest:
Dr. Han on the APHINITY Trial in HER2+ Early-Stage Breast CancerHeather S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.
Latest:
Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCLHeather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Latest:
Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLCThe panel discusses treatment considerations for consolidation durvalumab.
Latest:
Second-Line Treatment of SCLCVamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
Latest:
There's an App for That: Keeping Patients and Physicians on TrackIn a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.
Latest:
Heidi Donovan Discusses Prioritizing SymptomsHeidi Donovan from the University of Pittsburgh School of Nursing Discusses Prioritizing Symptoms
Latest:
Dr. Joensuu Discusses Resistance to Imatinib in GISTDr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia VeraHeinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.
